Amivantamab – March 2026

Solution concentrate for I.V. infusion 350 mg in 7 mL

  • Brand names:
    • Rybrevant®
  • Pharmaceutical Company:
    • JANSSEN-CILAG PTY LTD
  • Condition/Indication: Non-small cell lung cancer (NSCLC)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026